COGT vs NVS: How Cogent Biosciences and Novartis AG Compare (2026)
Last updated August 2026
Short answer
NVS is the larger of the two ($296.80B market cap): the incumbent the market prices for continued execution (15.82x forward earnings, beta 0.50). COGT is the smaller challenger ($7.24B), priced similarly on forward earnings (-44.87x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
COGT vs NVS: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | COGT | NVS | What it tells you |
|---|---|---|---|
| Market cap | $7.24B | $296.80B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -44.87 | 15.82 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.33 | 0.50 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 96% of range | 75% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 13.34 | 7.14 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how COGT and NVS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COGT and NVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COGT and NVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Cogent Biosciences (COGT) do?
Cogent Biosciences is a Waltham, Massachusetts and Boulder, Colorado biotechnology company building precision therapies for genetically defined diseases. Its lead asset, bezuclastinib, is a tyrosine kinase inhibitor designed to hit the KIT D816V mutation and other KIT exon 17 mutations. That single molecule underpins three indications: non-advanced systemic mastocytosis (the SUMMIT trial), advanced systemic mastocytosis (APEX), and gastrointestinal stromal tumors after imatinib, where it is paired with sunitinib (the PEAK trial). Behind bezuclastinib sits an early research portfolio aimed at ErbB2, PI3K alpha, KRAS and JAK2, with CGT4255 and CGT6297 entering Phase 1 in 2026 and IND filings planned for CGT1815 and CGT1145.
What does Novartis AG (NVS) do?
Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025.
COGT vs NVS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- COGT drivers: Three regulatory decisions inside twelve months; Systemic mastocytosis is the larger commercial prize.
- NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Everything routes through one molecule, so a complete response letter, a label restriction or a safety signal on any of the three applications hits the whole company at once. For NVS, the dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed.
COGT or NVS: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COGT if you believe its drivers more; NVS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COGT and NVS guides.
COGT vs NVS: the full fundamentals
COGT. There is no earnings multiple here because there are no earnings and no product sales, so the market is valuing probability-weighted future revenue from bezuclastinib across three indications. Net of roughly $866 million in cash and about $223 million of convertible notes, the enterprise value sits near $6.6 billion, which implies the market already assumes at least one approval and a credible launch. Quarterly cash burn ran near $87 million in the first quarter of 2026 and G&A more than doubled year over year on commercial build-out, so the burn rate rises before any revenue arrives.
NVS. Figures are approximate and qualitative, tied to the asOf date; verify live numbers before acting. The near-term picture is a revenue and profit dip as blockbusters lose exclusivity, so the stock is best judged on whether the newer growth brands and pipeline can restore mid-single-digit growth over the medium term rather than on a single trailing quarter.
Headline figures (approximate, August 2026): COGT shows market cap ~$7.2B, revenue (ttm) ~$0 (no approved product), net loss (ttm) ~$354M, cash and marketable securities (mar 31, 2026) ~$866M; NVS shows revenue (ttm) Approximately $50 billion in annual net sales; Q1 2026 net sales were about $13.1 billion, down roughly 5% at constant currency on generic erosion, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix growing well above 50% at constant currency, offsetting Entresto's decline, margins/profitability High core operating margin, around 40% in 2025; 2026 guidance is for a low single-digit decline in core operating income on generic and R&D pressure, dividend Pays an annual dividend with a long record of increases; yield has recently been roughly 2%, subject to currency and Swiss withholding tax for ADR holders.
The bottom line: COGT vs NVS
COGT and NVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COGT and NVS exposure against your real portfolio. It is not an investment adviser.
Wondering how COGT or NVS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Cogent Biosciences with AI
Connect the broker you already use and ask Walnut's AI how COGT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between COGT and NVS?
+
Cogent Biosciences is a Waltham, Massachusetts and Boulder, Colorado biotechnology company building precision therapies for genetically defined diseases. Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is COGT or NVS the better stock?
+
Neither is universally better. NVS is the larger incumbent; COGT is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, COGT or NVS?
+
On forward P/E (as of August 2026), COGT trades at -44.87x and NVS at 15.82x, so COGT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both COGT and NVS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of COGT vs NVS?
+
COGT: Everything routes through one molecule, so a complete response letter, a label restriction or a safety signal on any of the three applications hits the whole company at once. Bezuclastinib's history includes liver enzyme elevations that shaped dosing decisions, and tolerability is exactly what prescribers weigh when an alternative already exists. In systemic mastocytosis that alternative is avapritinib, now inside Sanofi after the Blueprint Medicines acquisition, which brings launch resources Cogent cannot match. The $866 million position funds operations into 2028 on management's plan, but a slower launch or a wider trial program means returning to equity markets, and the company has already used its at-the-market program and issued roughly $223 million of convertible notes. Finally, the stock trades near the top of a 52-week range that starts around $10, which leaves little cushion if any date slips. NVS: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. Pipeline risk is structural because late-stage trials can fail and regulators can reject or delay approvals, turning expected future revenue into a write-off. Large acquisitions such as Avidity add integration and financing risk and raised net debt. US drug-pricing policy, potential pharmaceutical tariffs, and pricing pressure are outside the company's control and could compress margins. Because NVS is a Swiss ADR, US investors also carry dollar-versus-Swiss-franc currency risk, and Swiss dividend withholding tax reduces net income for some holders. Concentration in a handful of growth drugs means a single clinical or commercial setback can move the stock.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell COGT or NVS; figures are approximate and dated (as of August 2026). Verify current data before investing.